Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003398 · ClinicalTrials.gov registry record · Phase 4
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
A Phase 4 study of Lymphoma and Leukemia, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT00003398: Completed Phase 4 study of Lymphoma and Leukemia, sponsored by University of Maryland, Baltimore.
NCT00003398 is a Phase 4 study of Lymphoma and Leukemia that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 45 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003398, a Phase 4 study of Lymphoma and Leukemia, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Bone marrow that has been treated to remove certain white blood cells may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy, and may reduce the chance of developing graft-versus-host disease following bone marrow transplantation. PURPOSE: Phase IV trial to study the incidence of graft-versus-host disease in patients who have hematologic cancer and who are undergoing bone marrow transplantation from a donor.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG thiotepa
- PROCEDURE allogeneic bone marrow transplantation
- BIOLOGICAL anti-thymocyte globulin
Study Locations (1)
Maryland
- Marlene & Stewart Greenebaum Cancer Center, University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 1998-09 |
| Est. Completion | 2000-05 |
| Phase | Phase 4 |
What the finished NCT00003398 record still lists
NCT00003398 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (91% lower).
The record links to 6 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003398 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00003398 about?
NCT00003398 is a clinical study titled "Bone Marrow Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Bone marrow that has been treated to remove certain white blood cells may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy, and may reduce the chance of developing graft-versus-host disease following bone marrow transplantation. PURPOSE: Phase IV t...
What is the current status of trial NCT00003398?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 1998-09. Estimated completion is 2000-05.
What conditions does trial NCT00003398 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Anemia, Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00003398?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), thiotepa (DRUG), allogeneic bone marrow transplantation (PROCEDURE), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003398?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003398 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003398's enrollment target sits among peer trials
45 163rd of 299 higher than 134 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vaccine Responses in Patients With B Cell Malignancies
RECRUITING · Phase 4
-
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
ACTIVE NOT RECRUITING · Phase 4
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia